B+
Bull case
30%
Probability
Target price
$50.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
EWTX
Edgewise TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The May 7, 2026 update kept the two most important clinical milestones intact: Q2 2026 CIRRUS-HCM data and Q4 2026 GRAND CANYON pivotal Becker data. The filing also showed $499.6 million of cash, cash equivalents and marketable securities at March 31, 2026, while the 10-Q says existing liquidity should fund planned operating expenses and capital expenditures for at least the next 12 months [#10-Q-2026-05-07].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +1.3.
What can break
Clinical readouts in HCM or Becker could miss on efficacy, safety, or interpretability, which would pressure a pipeline-led valuation.
Momentum
64
Value
41
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $40.00 · Bull $50.00 · Bear $24.00Analysis 2026-05-09; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $51.69
Why
Momentum64 · Δ7d +7.9
Value41 · Δ7d 0.0
Sentiment51 · Δ7d +1.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +1.3.
Contradictions & invalidation
- • Clinical readouts in HCM or Becker could miss on efficacy, safety, or interpretability, which would pressure a pipeline-led valuation.
- • Late-stage execution risk remains high around GRAND CANYON enrollment, data quality, and eventual regulatory positioning for sevasemten.
- • This remains a high-dependency binary biotech story with no commercial revenue, higher year-over-year R&D spend, and value concentrated in upcoming clinical readouts.
Catalyst clock
2026-06-30
CIRRUS-HCM 12-week Part D data due in Q2 2026
Lead driver: Sentiment · See AI snapshot
Momentum
64
9% active weight
Current posture
7d trendImproving
Δ7d
+7.9
Δ21d
-20.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
51
62% active weight
Current posture
7d trendImproving
Δ7d
+1.3
Δ21d
+2.9
Why this grade
Composite grade D. Momentum 64.4 / Value 41.2 / Sentiment 51.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-09. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$40.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-05-09 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$4.78B
Beta
0.28
Shares Out
108.6M
P/E (TTM) · Derived
-27.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-29.57
Rev YoY
-
EPS YoY
+54.7%
Gross Margin
-
Op Margin
-
Net Debt
-$526.12M
Current Ratio
16.24
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data